In this phase 3 trial, older patients with acute myeloid leukemia ineligible for intensive
chemotherapy were randomized 2: 1 to receive the polo‐like kinase inhibitor, volasertib (V; …

High-dose cytarabine (HiDAC) consolidation for acute myeloid leukemia (AML) induces
transient profound myelosuppression and potential morbidity/mortality. PrE0901 was a …

In summary, this article suggests that perifosine (or potentially other agents targeting the
phosphoinositol-3-kinase-AKT signaling) is an effective and relatively nontoxic agent for the …

Conventional treatments for acute leukemia include chemotherapy, radiation therapy, and
intensive combined treatments (including bone marrow transplant or stem cell transplants) …

Purpose. The significance of vascular endothelial growth factor receptor (VEGFR)‐2 in
numerous solid tumors and acute myeloid leukemia (AML) has been demonstrated, but …

Polo-like kinase 1 (Plk1) plays a number of important roles in the passage of cells through
mitosis. It is expressed at high levels in a variety of malignancies, including acute myeloid …

Significant progress in the treatment of acute lymphoblastic leukemia (ALL) has been
achieved through more effective use of established drugs in risk-adapted treatment …

ABSTRACT Introduction: The management of Acute Myeloid Leukemia (AML)(with the
exception of acute promyelocytic leukemia) has remained largely unchanged over the past …

Forodesine is a potent, specific transition-state analog inhibitor of PNP with clinical activity in
T-cell malignancies. Pharmacodynamic studies support that this anti-leukemic effect is …

Clinical outcomes of patients with acute myeloid leukemia (AML) showing the first primary
refractory or early-relapsed disease remain very poor. The Programa Español de …